The Cdk5 inhibitor olomoucine promotes corneal debridement wound closure in vivo by Tripathi, Brajendra K. et al.
The Cdk5 inhibitor olomoucine promotes corneal debridement
wound closure in vivo
Brajendra K. Tripathi,1 Mary A. Stepp,2 Chun Y. Gao,1 Peggy S. Zelenka1
1Laboratory of Molecular and Developmental Biology, National Eye Institute, National Institutes of Health, Bethesda, MD;
2Department of Anatomy, George Washington University Medical Center, Washington, DC
Purpose: To investigate the effect of the Cdk5 inhibitor olomoucine on corneal debridement wound healing in vivo.
Methods: Corneal debridement wounds of 1.5 mm were made on the ocular surface of CD-1 mice. A 20 μl drop of 15
µM olomoucine in 1% DMSO was applied to the wound area immediately after wounding and again after 6 h. Control
mice received identical applications of 1% DMSO. Mice were euthanized after 18 h, two weeks, and three weeks for
evaluation of wound healing and restratification. Corneas were stained with Richardson’s dye, photographed, and
processed for histology and immunofluorescence as whole mounts or paraffin sections. The remaining wound area at 18
h was measured by image analysis. Scratch wounded cultures of human corneal-limbal epithelial cells (HCLE) were used
to examine the effect of olomoucine on matrix metalloproteinase (MMP) expression in vitro. MMP-2 and MMP-9 were
detected by immunofluorescence and immunoblotting.
Results:  Olomoucine  treatment  significantly  enhanced  corneal  wound  closure  without  increasing  inflammation  or
infiltration of polymorphonuclear leukocytes 18 h after wounding (p<0.05). The increased localization of MMP-9 within
epithelial cells at the wound edge was further enhanced by olomoucine while the expression of MMP-2 was reduced.
Olomoucine treatment of scratch wounded HCLE cells produced similar changes in MMP-9 and MMP-2 expression. The
examination of treated corneas two and three weeks after wounding showed normal epithelial restratification with no
evidence of inflammation or stromal disorganization.
Conclusions:  Topical  application  of  olomoucine  in  1%  DMSO  significantly  enhances  closure  of  small  epithelial
debridement wounds without increasing inflammation or impairing reepithelialization.
Cells  along  the  leading  edge  of  corneal  debridement
wounds  undergo  specific  changes  in  gene  expression,
cytoskeletal organization, and signaling that enable them to
maintain  tight  connections  with  neighboring  cells  while
migrating rapidly to cover the wound [1]. Among the changes
observed in these cells is a specific activation of the Ser/Thr
kinase, Cdk5 [2]. Cdk5 activity in this region was shown to
limit the accumulation of active Src at the plasma membrane
[2]. Active Src stimulates the formation of lamellipodia and
the dynamic turnover of cell-cell junctions thus promoting
epithelial cell migration [3]. However, excessive Src activity
can also cause degradation of E-cadherin [4] and a complete
loss  of  cell-cell  adhesion,  leading  to  epithelial-to-
mesenchymal  transition  (EMT)  [5],  so  its  activity  and
localization must be stringently controlled. By limiting the
accumulation  of  active  Src  along  the  leading  edge,  Cdk5
protects the integrity of the epithelial cell sheet but somewhat
reduces  the  rate  of  cell  migration.  Thus,  inhibiting  Cdk5
activity  in  organ  culture  after  debridement  wounding
enhances  the  formation  of  lamellipodia  and  significantly
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increases the rate of migration but also causes some separation
of  cells  along  the  leading  edge  [2].  Conversely,  the
overexpression  of  Cdk5  in  corneal  epithelial  cells  of
transgenic mice significantly reduces the rate of debridement
wound closure [2]. The ability of Cdk5 inhibitors to increase
epithelial  cell  migration  during  wound  closure  in  organ
culture suggested that the pharmacological manipulation of
Cdk5  activity  might  be  therapeutically  useful  in  some
situations if it did not interfere with cell-cell adhesion or
produce  other  detrimental  effects  [6].  In  this  study,  we
examine the feasibility of this approach by testing the ability
of the Cdk5 inhibitor, olomoucine, to promote closure of small
corneal epithelial debridement wounds in mice.
METHODS
Corneal  debridement:  All  procedures  conformed  to  the
guidelines provided by the Association for Research in Vision
and Ophthalmology and the National Institutes of Health,
Bethesda, MD. Six-week-old male CD-1 mice (approximately
20  g)  were  purchased  from  Charles  River  Laboratories
(Wilmington,  MA)  and  housed  under  standard  laboratory
conditions;  water  and  food  were  continuously  available.
Animals  were  anesthetized  with  a  mixture  of  ketamine
(70 mg/kg), xylazine (7 mg/kg), and acepromazine (10 mg/
kg). Small (1.5 mm) corneal debridement wounds were made
as previously described with minor modifications [7]. One
Molecular Vision 2008; 14:542-549 <http://www.molvis.org/molvis/v14/a66>
Received 28 December 2007 | Accepted 10 March 2008 | Published 17 March 2008
© 2008 Molecular Vision
542group of mice was euthanized immediately after wounding
(t=0  h)  for  measurements  of  the  initial  wound  area.  The
remaining  mice  were  divided  into  treatment  and  control
groups. The treatment group received 15 μM olomoucine
(Sigma, Indianapolis, IN), which was prepared in phosphate
buffered saline (PBS; Invitrogen, Carlsbad, CA) containing
1%  DMSO.  The  control  group  received  1%  DMSO  in
phosphate buffered saline. Olomoucine was applied twice (at
0 h and 6 h) as a single drop (20 μl) to the central cornea of
the injured eye with the lower eyelid held away from the eye
to  avoid  overflow.  Both  groups  received  erythromycin
ophthalmic ointment to keep the cornea moist and to prevent
infection.
Histological analysis: For photography of corneal abrasions,
animals were euthanized 18 h, two weeks, and three weeks
after  wounding.  Eyes  were  removed,  fixed  with  4%
paraformaldehyde,  and  stained  with  Richardson’s  dye.
Photomicrographs were taken using an Olympus dissecting
microscope (Olympus, Center Valley, PA), and the remaining
wound area was measured by image analysis using Image
ProPlus (Media Cybernetics, Pleasanton, CA). Images were
identified only by code until measurements were completed
to avoid experimenter bias. For sectioning, enucleated eyes
were fixed for 24 h in 4% paraformaldehyde (for paraffin
sections) or 10% formalin (for methacrylate sections) and
embedded accordingly. Corneal sections (6 μm) were stained
with  hematoxylin  and  eosin  and  evaluated  by  light
microscopy.
Figure  1.  Olomoucine  treatment  promotes  corneal  re-
epithelialization  in  normal  mice.  A:  Eyes  were  stained  with
Richardson’s stain immediately after debridement wounding (0 h) or
18 h afterward. At 0 h and 6 h after wounding, control animals
received a sterile vehicle (1.0% DMSO in PBS) and the treatment
group received 15 μM olomoucine. Scale bar=100 μM. B: The graph
shows the remaining wound area as a percentage of average initial
wound area (mean ± SEM). The difference between olomoucine-
treated and control mice was statistically significant (p<0.05; n=28–
30).
Cell culture: Human corneal limbal epithelial (HCLE) cells
were grown to confluency at 37 °C in a humidified atmosphere
of  95%  air  and  5%  CO2  in  Keratinocyte-SFM  medium
(Invitrogen) supplied with pre-qualified human recombinant
epidermal  growth  factor  1–53  (EGF  1–53),  and  bovine
pituitary extract (BPE). The medium was supplemented with
0.3 mM calcium chloride (Invitrogen) and 50 µg/ml penicillin/
streptomycin.
Scratch wounding and immunoblotting: For in vitro analysis
of protein expression, HCLE cells were seeded onto 60 mm
dishes  coated  with  a  fibronectin-collagen  coating  mixture
(Biologic  Research  Faculty  &  Facility,  Ijamsville,  MD),
grown to 90% confluence, and scratch wounded by multiple
linear scrapes with a sterile 20 μl pipette tip. After washing
away  debris,  the  cells  were  re-fed  with  the  medium.
Olomoucine (15 μM) was added to experimental samples for
Figure 2. Olomoucine treatment does not disrupt the integrity of the
epithelial cell sheet. A: The immunofluorescence of E-cadherin in
epithelial cells of corneal whole mounts of control animals shows
tightly packed epithelial cells with a smooth, advancing cell front.
Cells were compact and cell density was high especially along the
wound edge. B: Higher magnification of the boxed area shown in
panel  A  shows  that  E-cadherin  immunofluorescence  in  control
corneas  was  confined  almost  entirely  to  cell-to-cell  boundaries.
Punctate E-cadherin staining was seen at the migrating front on the
edge lacking cell-to-cell contacts (arrowhead). C: Superimposition
of E-cadherin immunostaining and DAPI-staining of nuclei confirms
that E-cadherin is located at cell-to-cell boundaries and that all cells
express E-cadherin. D: In olomoucine-treated corneas, cell density
was appreciably lower and the migrating front was irregular. Cell-
to-cell junctions appeared to be intact except for a few cells at the
wound  edge.  Immunostaining  of  E-cadherin  was  weak  or
undetectable at the migrating front on the edge lacking cell-to-cell
contacts (arrowhead). E: Higher magnification of the boxed area
shown  in  panel  D  demonstrates  punctate  intracellular
immunostaining for E-cadherin in many cells (single arrows). E-
cadherin localization at cell-to-cell junctions was disrupted in a few
cells along the wound edge (double arrows). F: Superimposition of
E-cadherin  immunofluorescence  and  DAPI-staining  of  nuclei
confirms that E-cadherin is located at cell-to-cell boundaries and
demonstrates that all cells express E-cadherin. Scale bar=100 μM in
A,C,D, F; 40 μM in B,E.
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5436 h immediately after wounding. Control samples were treated
identically except that olomoucine was omitted. After 6 h of
treatment, cells were lysed in PBSTDS buffer (1X phosphate
buffered saline, 1% Triton X-100, 0.5% sodium deoxycholate,
0.1% SDS containing Complete™ protease and phosphatase
inhibitor), and immunoblotting was performed as described
previously [8].
Antibodies:  Anti-MMP-2  and  anti-MMP-9  polyclonal
antibodies were purchased from Abcam Inc., (Cambridge,
MA).  Anti-E-cadherin  polyclonal  antibody  was  purchased
from Cell Signaling Technology (Beverly, MA). Alexa 488-
conjugated and Alexa 568-conjugated anti-rabbit IgG and
DAPI were purchased from Molecular Probes (Eugene, OR).
Immunofluorescence  and  confocal  microscopy  of  whole
mount cornea: After treatment, eyes were removed, fixed,
rehydrated and stained with anti-MMP-2, anti-MMP-9 and
anti-E-cadherin antibodies according to previously described
protocol [9]. After staining, the corneal tissues were removed
and  washed  in  PBS  and  whole-mounted  on  Superfrost
microscope  slides  (Erie  Scientific  Company,  Portsmouth,
NH) for laser scanning confocal microscopy (Leica TCS SP2,
Leica Microsystem, Germany) as previously described [10].
Immunohistochemical  staining  of  MMP-2  and  MMP-9  in
paraffin  sections:  Formalin-fixed,  paraffin-embedded
sections  (6  μm)  were  deparaffinized  with  xylene  and
rehydrated through a graded alcohol series. Samples were
permeabilized in 0.25% Triton X-100 in PBS for 10 min and
incubated with 5% normal goat serum in PBS for 2 h to block
non-specific sites. Sections were incubated overnight at 4 °C
with  the  primary  antibody  at  a  dilution  of  1:150  (V/V).
Sections  were  extensively  washed  in  phosphate  buffered
saline and then incubated with Alexa 488-conjugated or Alexa
Figure  3.  Olomoucine  does  not  increase  infiltration  of
polymorphonuclear  neutrophils  (PMNs)  18  h  after  debridement
wounding. The counting of PMNs in the photomicrograph of corneal
sections  stained  with  hematoxylin/eosin  showed  no  significant
difference in the average total number of PMNs per section. The
examination of specific regions indicated a significant reduction in
the number of PMNs in the central cornea (p<0.05; n=10), which was
compensated by small increases in the limbus and anterior chamber.
568-conjugated  anti-rabbit  IgG  (Molecular  Probes)  at  a
dilution of 1:250 (V/V). Sections were counterstained with
DAPI at a dilution of 1:2500 in PBS (V/V) for nuclear staining
and  mounted.  Negative  controls  contained  no  primary
antibody.
Data  analysis:  Data  were  analyzed  by  ImagePro  Plus
(MediaCybernetics, Silver Spring, MD) and/or ImageQuant
(GE Healthcare, Piscataway, NJ) image analysis software.
Values of all data are expressed as mean ± standard error
mean. For statistical analysis of data sets, Student’s t-test was
performed using SigmaPlot (Systat, San Jose, CA) software
and a p<0.05 was considered statistically significant.
RESULTS
In vivo corneal wound closure: A mouse corneal debridement
wound model was used to test the effect of olomoucine on
corneal epithelial wound closure in vivo. The central cornea
was demarcated with a 1.5 mm trephine, and debridement
wounds were made without encroaching on the limbus or
conjunctiva. The initial wound area varied less than 5% as
determined  by  image  analysis  of  the  stained  cornea  (not
shown). Mice were given two topical applications of 15 μM
olomoucine in 1% DMSO, one immediately after wounding
and the other 6 h later. Control animals received equivalent
treatments with 1% DMSO only. Animals were euthanized
after  18  h  and  the  remaining  wound  area  was  stained,
photographed,  and  measured  by  image  analysis  software.
Images were identified only by code to avoid experimenter
bias during the measurements. The results showed that the
remaining wound area in olomoucine-treated corneas was
Figure 4. Olomoucine treatment supported normal restratification of
the  corneal  epithelium.  Photomicrographs  of  hematoxylin/eosin
stained sections of the restratified wound area of olomoucine-treated
and untreated control corneas two and three weeks after corneal
abrasion revealed no apparent differences in epithelial morphology
or stromal organization. W=week; E=epithelium; S=stroma. Scale
bar=100 μM.
Molecular Vision 2008; 14:542-549 <http://www.molvis.org/molvis/v14/a66> © 2008 Molecular Vision
544significantly  less  than  in  controls,  indicating  that  in  vivo
treatment with olomoucine enhances epithelial wound closure
(Figure 1A,B).
E-cadherin  localization  in  olomoucine-treated  corneas:
Since previous studies had suggested that inhibition of Cdk5
activity might also affect E-cadherin junctional stability, we
examined E-cadherin localization in treated and untreated
corneas 18 h after wounding. In control corneas, E-cadherin
immunostaining  was  confined  almost  entirely  to  cell-cell
boundaries (Figure 2). Only cells at the leading edge, which
lacked  cell  contacts  on  one  surface,  showed  appreciable
cytoplasmic staining of E-cadherin. Cells were compact and
cell density was high especially along the wound edge. In
contrast,  in  olomoucine-treated  corneas,  cells  were  more
spread  and  cell  density  was  appreciably  lower.  Cell-cell
junctions appeared to be intact for the most part, although
many cells contained E-cadherin positive vesicles (Figure 2).
Small disruptions in the migrating front suggest there may be
some loss of cell-cell adhesion in this region, but it is not
widespread.
Polymorphonuclear  leukocyte  (PMN)  infiltration:  To
determine whether olomoucine treatment affects neutrophil
infiltration, we counted the number of polymorphonuclear
leukocytes  (PMNs)  present  in  the  limbal  stroma,  corneal
stroma, and anterior chamber of hematoxylin/eosin stained
methacrylate sections of olomoucine-treated and control eyes.
PMNs  were  identified  by  nuclear  morphology,  and  two
sections from each of the 10 eyes were used in each group. As
before,  sections  were  identified  only  by  code  to  avoid
experimenter bias. The results showed that PMN infiltration
of the corneal stroma was significantly less in olomoucine-
treated eyes (p<0.05). In contrast, the number of PMNs in the
limbal stroma and anterior chamber of treated eyes was not
significantly different from controls (Figure 3).
Restratification:  To  assess  the  long-term  effects  of
olomoucine  treatment  on  restratification  of  the  corneal
surface, we examined the corneal histology of seven paraffin
sections from each of the five treated and five untreated eyes
two  and  three  weeks  after  wounding.  We  observed  no
difference in epithelial thickness or number of cell layers
within the original wound area of olomoucine-treated corneas
when  compared  to  untreated  controls.  Epithelial  cells
appeared to adhere well to each other and to their basement
membrane. Treated corneas also showed no abnormalities in
basement  membrane  thickness,  stromal  organization,  or
keratocyte number (Figure 4).
Matrix  metalloproteinase  expression:  Since  matrix
metalloproteinases play an important role in corneal epithelial
cell migration [11], we next determined whether inhibition of
Cdk5  by  olomoucine  also  affected  MMP  expression  by
examining  corneal  whole-mounts  and  paraffin  sections,
which  were  immunostained  with  antibodies  specific  for
MMP-9 and MMP-2. Untreated controls showed increased
expression of MMP-9 in several rows of cells surrounding the
wound  margin  as  previously  reported  [12].  MMP-9
expression was seen primarily on the basal aspect of basal
Figure  5.  Olomoucine  treatment
increased  the  localization  of  MMP-9
protein in epithelial cells at the wound
edge. A: MMP-9 immunofluorescence
is  elevated  at  the  wound  edge  in
untreated  control  corneas  (arrow).  B:
The immunostaining of MMP-9 at the
wound edge (arrow) is further enhanced
in  olomoucine-treated  corneas.  C:
Whole  mounted  corneas  without  any
primary  antibody  showed  no
immunofluorescence.  D:  Paraffin
sections  of  wounded  control  corneas
showed  MMP-9  immunofluorescence
in all layers of the cornea at wound edge
(arrow)  and  in  basal  epithelial  cells
distal  to  the  wound  (arrowhead).  E:
Paraffin section of olomoucine-treated
corneas  showed  intense  MMP-9
immunofluorescence in a wider band of
cells  at  the  wound  edge.
Immunofluorescence was seen in cells
of all layers of the epithelium (arrow).
F: No immunostaining was detected in
the paraffin sections of corneas when
primary MMP-9 antibody was omitted.
Scale bar=100 μM.
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545cells. In the olomoucine-treated eyes, the immunostaining of
MMP-9 appeared more intense and more cells were positively
stained in both the whole mounts and paraffin sections (Figure
5).
It is known that MMP-2 (gelatinase A) participates in
epithelial repair and stromal remodeling [12]. To determine
whether olomoucine affects the expression of MMP-2 in the
wounded  corneal  epithelium,  whole  mounted  corneas  and
paraffin sections were immunostained for MMP-2. In contrast
to the results seen for MMP-9, immunofluorescence of this
matrix  metalloproteinase  was  significantly  less  in  corneal
epithelium upon treatment with olomoucine in both the whole
mounted corneas and the paraffin sections (Figure 6).
We  confirmed  the  effect  of  olomoucine  on  MMP
expression  by  immunoblotting  proteins  extracted  from
cultured human corneal epithelial cell line (HCLE) before and
after  scratch  wounding  to  simulate  the  effect  of  corneal
debridement.  Immunoblotting  with  anti-MMP-9  antibody
detected a single immunoreactive band of approximately 
92 kDa that comigrated with purified MMP-9 protein, thus
confirming its specificity (not shown). Scratch wounding of
confluent cultures produced a significant increase in MMP-9
expression, which was further increased in the presence of
olomoucine  (p<0.05;  Figure  7A,B).  Immunoblotting  also
demonstrated a significant decrease in MMP-2 expression,
which was further decreased by olomoucine (p<0.05; Figure
8A,B). Thus, treatment with olomoucine specifically alters the
expression levels of MMP-9 and MMP-2 in corneal epithelial
cells in vitro as well as in vivo.
DISCUSSION
The  results  of  this  study  demonstrate  that  the  topical
application of olomoucine increases the rate of debridement
wound  closure  in  mice  without  causing  appreciable
dissociation or detachment of epithelial cells. While these
positive  findings  suggest  that  Cdk5  inhibitors  may  hold
promise for treating corneal erosions, some problems remain.
Most importantly, all currently available Cdk5 inhibitors also
significantly inhibit other members of the cyclin dependent
kinase family, which are essential for cell proliferation [6,
13]. However, since proliferation is not required for closure
of small debridement wounds of the type used in this study
[14,15], the potential inhibition of proliferation has not posed
a  problem.  Moreover,  since  olomoucine  is  a  reversible
inhibitor, its effects are transient when it is applied topically,
as shown by the normal restratification observed two and three
weeks  after  wounding.  These  results  suggest  that  the
inhibition of Cdk5 with olomoucine or other Cdk5 inhibitors
may be a useful treatment strategy for small debridement
wounds; however, its therapeutic potential in other situations
requires further study.
The results of this study also showed that olomoucine did
not increase the infiltration of inflammatory cells into the
corneal stroma as measured 18 h after wounding. Neutrophils
normally  promote  epithelial  cell  proliferation  and  wound
closure  possibly  by  releasing  growth  factors  stored  in
neutrophil granules [16,17]. However, infiltration must be
strictly regulated since excessive infiltration and the ensuing
Figure  6.  Olomoucine  treatment
decreased  localization  of  MMP-2
protein at the wound edge. A: MMP-2
immunofluorescence is elevated at the
wound  edge  in  untreated  control
corneas.  B:  The  immunostaining  of
MMP-2 at the wound edge (arrow) is
reduced in olomoucine-treated corneas.
C:  Whole  mounted  corneas  without
primary  antibody  showed  no
immunofluorescence.  D:  Paraffin
sections  of  wounded  control  corneas
showed  MMP-2  immunofluorescence
in all layers of the cornea at wound edge
(arrow)  and  in  basal  epithelial  cells
distal to the wound (arrowhead). E: The
paraffin section of olomoucine-treated
cornea  showed  reduced
immunofluorescence of MMP-2 at the
wound  edge  (arrow).  MMP-2
immunofluorescence  persisted  in  the
basal layers of epithelium (arrowhead).
F: No immunostaining was detected in
the paraffin section of the cornea when
primary MMP-2 antibody was omitted.
Scale bar=100 μM.
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546inflammation are damaging [18]. The presence of normal
numbers  of  neutrophils  in  treated  corneas  indicates  that
olomoucine  does  not  disrupt  the  regulatory  processes
governing neutrophil infiltration. When regions of the cornea
were examined separately, the average number of neutrophils
in the central cornea was somewhat less in treated animals
than in controls, while the average numbers in the limbal
region and the anterior chamber were slightly more. This
suggests that olomoucine may have a slight effect on the rate
of infiltration, although the total number of infiltrating cells
was not affected.
An additional finding of this study is the novel effect of
olomoucine  on  matrix  metalloproteinase  expression.
Expression of MMP-9, which is normally induced along the
wound edge, was further enhanced by olomoucine treatment.
Conversely,  olomoucine  suppressed  the  expression  of
MMP-2, which is constitutively expressed in the basal cells
Figure  7.  Olomoucine  treatment  significantly  increases  MMP-9
expression  in  HCLE  cells  after  scratch  wounding.  A:
Immunoblotting of protein extracts of HCLE cells with MMP-9
antibody detected a single immunoreactive band of approximately
92 kDa. Lane 1 shows that cultured cells expressed MMP-9 before
scratch wounding. Lane 2 illustrates that scratch wounding increased
MMP-9  expression  detected  18  h  afterward.  Lane  3  shows  that
scratch wounding followed by 18 h incubation with olomoucine
further  increased  MMP-9  expression.  B:  The  results  of
immunoblotting experiments were quantified by densitometry (n=4).
Statistical analysis demonstrated a significant increase in MMP-9
expression (p<0.05) in scratch wounded cultures when compared to
unwounded  cultures  and  in  scratch  wounded  cultures  with
olomoucine when compared to those without it. Graph represents
mean ± SEM. Values are normalized to unwounded controls.
[19]. MMP-9 is known to play an important role in regulating
corneal epithelial cell migration [11]. Previous studies have
linked the induction of MMP-9 transcription along the wound
edge to upregulation of Pax6, a transcription factor which
binds directly to the MMP-9 promoter [20]. Since the effect
of olomoucine on Pax6 expression has not yet been examined,
it is not clear whether olomoucine affects this same pathway.
However, there are many potential mechanisms due to the
regulation  of  MMP-9  expression  being  complex  and
Figure  8.  Olomoucine  treatment  significantly  decreases  MMP-2
expression  in  HCLE  cells  after  scratch  wounding.  A:
Immunoblotting of protein extracts of HCLE cells with MMP-2
antibody detected a single immunoreactive band of approximately
68 kDa. Lane 1 shows that cultured cells expressed MMP-2 before
scratch wounding. Lane 2 illustrates that scratch wounding decreased
MMP-2 expression detected 18 h afterward. Lane 3 also shows that
scratch wounding followed by 18 h incubation with olomoucine
further  decreased  MMP-2  expression.  B:  The  results  of
immunoblotting experiments were quantified by densitometry (n=4).
Statistical analysis demonstrated a significant decrease in MMP-2
expression (p<0.05) in scratch wounded cultures when compared to
unwounded  cultures  and  in  scratch  wounded  cultures  with
olomoucine when compared to those without it (p<0.05). Graph
represents  mean  ±  SEM.  Values  are  normalized  to  unwounded
controls.
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547involving  the  concerted  action  of  multiple  other  factors
including AP-1, AP-2, SP-1, and NF-κB [11]. Moreover, Src
plays an important role in regulating MMP transcription in
many  cell  types  by  interacting  with  upstream  signaling
pathways [21-23]. Since previous studies from this laboratory
have  shown  that  olomoucine  treatment  increases  the
concentration of active Src along the wound edge [2], it will
be  particularly  interesting  to  examine  the  possible
involvement  of  Src  family  kinases  in  regulating  MMP
expression in these cells.
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